$56.60 now> UPDATE- (and reply to email) UBS upgrades Birkenstock to Buy on direct-to-consumer expansion UBS upgraded Birkenstock(BIRK)to Buy from Neutral with a price target of $85, up from $52. The company is successfully executing its direct-to-consumer expansion strategy better than expected, the firm tells investors in a research note. UBS sees Birkenstock "ramping rapidly" in Asia-Pacific and selling prices moving higher than previously thought, driven by a positive sales mix shift to direct-to-consumer and successful introductions of premium priced products in new categories. The firm increased its five-year annual earnings growth forecast to 25% from 21% and its new fiscal 2026 earnings estimate is now 10% above consensus. UBS thinks continued strong growth and upward earnings revisions will boost the stock's valuation toward its price target. It sees a 3:1 upside/downside skew.
UP Wheels Up Experience Inc.- I screwed this up. I spotted the Alpha coming into this name and didn't follow through. Then it was up 3 days... $4.00 0.76(+23.46%)4:00 PM 07/05/24
Regarding Carrier> This news not factored in enough! Carrier completes sale of industrial-fire business for $1.425B<------------------- This is dated July 2..... There is so much carrier can do with those dollars.. pay down debt, buy back shares...
Regarding Solid Bio- mixed bag/ We have a 17% increase in institutions 12 new buys <-- There are 81 funds or institutions reporting positions in Solid Biosciences. This is an increase of 12 owner(s) or 17.39% in the last quarter. Average portfolio weight of all funds dedicated to SLDB is 0.24%, an increase of 153.13%. Total shares owned by institutions increased in the last three months by 109.70% to 35,072K shares.Thep Van: put/call ratio of SLDB is 1.72, indicating a bearish outlook.
Do you trade Harry Boxer's Gap Up strategy Stoney. Whilst his Book was a severe disappointment, that is a popular strategy espoused by many.
THE BIO-KING REPORT: SLDB Fintel reports that on June 24, 2024, Leerink Partners upgraded their outlook for Solid Biosciences (NasdaqGS:SLDB) from Market Perform to Outperform. Analyst Price Forecast Suggests 160.53% Upside As of June 12, 2024, the average one-year price target for Solid Biosciences is 16.83. The forecasts range from a low of 12.12 to a high of $21.00. The average price target represents an increase of 160.53% All of this does not tell the whole story though: 1- Shares of Solid Bio spent two years in free fall from early 2021 to late 2023. 2- Chasing SRPT: William Blair analyst Tim Lugo says Solid Bio could be a fast follower in Duchenne muscular dystrophy. Sarepta Therapeutics(SRPT) has the only approved gene therapy on the market for the disease, which primarily affects boys and causes progressive muscle weakness. 3-Solid Bio's drug works by helping a patient's body make a miniature version of the dystrophin protein. Dystrophin keeps muscles intact, but it's missing in patients with Duchenne muscular dystrophy. In mice, Solid Bio's gene therapy led to high levels of dystrophy expression. "Given the 100% expression viewed in several areas of the mouse model, we believe expression data should be strong, and if the safety profile is clean, we would expect this to be a catalyst for shares to spike severalfold," Lugo said. 4- Now when this analyst was talking about severalfold (great word) Solid was $13. // We are now getting it for much less.. sEveralfold from $13...= $36//<--- GBA TARGET*** Solid Bio is working on a treatment for catecholaminergic polymorphic ventricular tachycardia, or CPVT. This inherited disorder causes sudden heart rhythm disturbances, also called arrhythmias, in healthy children. CPVT is "a potentially even larger driver of value than DMD given the company's lead position in this deadly disease that impacts 20,000 people in the United States alone," he said. "Solid's program also holds several possibilities for fast-to-market clinical trial design." <<< Alright all of that is well and good but there's more... A) We just joineD the Russell 3000 B) FDA's Sarepta decision 'positive' for gene therapy, STATNews reports » 06/21 SRPT, SLDB<----- C) Piper sees opportunity for Solid Biosciences after broad Elevidys approval » 06/21 SLDB, SRPT<------ D) Solid Biosciences expects cash to fund strategic priorities into 2026 » 05/15 SLDB E) Pfizer had a setback in this same field... and that ignited SRPT... Sarepta gains after Pfizer’s late-stage setback for Duchenne therapy NewsThu, Jun. 13 F) Pfizer DMD gene therapy miss paves way for Sarepta, Solid Biosciences, says Citi » 06/13 SRPT, SLDB, PFE Ok so SRPT already fired /// SLDB is up next.... (Hopefully) I will be buying Solid this Monday or Tues.
Oh my God! You know Harry. Boxer and I go way back. I was part of his website years ago. The Technical Trader. I was a bit of a star over there... Harry is fantastic. I have great great respect for the man. The trouble is he just gives you too many ideas. And it made me crazy. I don't like to over trade. Harry is fine trying out shit and dumping; I fall in love and over research everything. Harry is just about the momentum.. but my method is based off his in away. If you notice every gummy is a gap up but I buy not at the open but in the 10:30 retrace window. From my work: 10:30 almost always brings you a retrace. So we go by the amount of the gap.. I will send into the HF daily roughly 4 or 5 names and they watch them on the desk and whichever moves out the most they buy for me at 10:30. It's a simple system that works!!!! Kudos to you know for the TT. Great guy. I miss our times together.
Darc tell me more about Australia where would you go for the best visiting experience-? it is such a big country people have told me once you fly all the way fuck there you should keep going to the other side of Australia?
I knew you knew him. You said you were in his Trading Room for awhile. That Gap strategy is the one he espouses the most in his Book. It's seems to be quite valid. There's a YouTube vid of Harry and @KCalhoun at a Trading conference in Vegas. Ken introduces Harry. They are great Buddies.
There is a stock called CVM Cel-Sci I think they are still around//and way back 2018 or so I was pushing Harry on CVM he had a chat room back then...and it was under $2.00 he put it in his chart review and it skyrocketed to $20 and that's how we formed a friendship (virtual) I also gave him REKR it went from $4 to over $20.